Get the Stockscreener App
354.85
0.14%
-0.50
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $354.85, with a volume of 1.40M.
It is down -0.14% in the last 24 hours and up +3.84% over the past month.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$355.35
Open:
$355.17
24h Volume:
1.40M
Relative Volume:
1.02
Market Cap:
$68.84B
Revenue:
$321.33B
Net Income/Loss:
$1.57B
P/E Ratio:
44.63
EPS:
7.9518
Net Cash Flow:
$3.21B
1W Performance:
+5.71%
1M Performance:
+3.84%
6M Performance:
+19.15%
1Y Performance:
+47.31%
1-Day Range:
$352.42
$356.87
1-Week Range:
$333.95
$356.87
52-Week Range:
$237.71
$377.54
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
354.85 | 68.94B | 321.33B | 1.57B | 3.21B | 7.9518 |
|
MCK
Mckesson Corporation
|
840.46 | 104.19B | 387.09B | 4.23B | 6.01B | 32.12 |
|
CAH
Cardinal Health Inc
|
212.45 | 50.72B | 234.31B | 1.61B | 4.45B | 6.6243 |
|
HSIC
Henry Schein Inc
|
79.98 | 9.19B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.5902 | 840.28M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Aug Volume: Is Cencora Inc benefiting from interest rate changesPortfolio Gains Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Aug Spikes: What dividend growth rate does Cencora Inc offerJuly 2025 Macro Moves & Real-Time Volume Analysis - baoquankhu1.vn
Cencora Sets Date to Reveal Q1 Results as Investors Brace for Early Look - MyChesCo
Cencora Expands Credit Facilities to Finance OneOncology Deal - TipRanks
Cencora Updates Multiple Financing Agreements With Major Lenders - TradingView — Track All Markets
Cencora (NYSE: COR) expands credit lines to fund OneOncology acquisition - Stock Titan
Cencora, Inc. Enters into an Incremental Facility and Amendment Agreement - marketscreener.com
Portfolio Recap: Is RCEL stock a good dividend stockJuly 2025 Macro Moves & Verified Trade Idea Suggestions - baoquankhu1.vn
NJ Judge Orders Mediation In Merck-Cencora Indemnity Fight - Law360
10 Biggest Healthcare Companies - Investopedia
Aug Reactions: Is Cencora Inc stock a defensive play in 2025Oil Prices & Long-Term Safe Return Strategies - Bộ Nội Vụ
Breakout Zone: Will Cencora Inc. stock benefit from AI adoptionMarket Risk Report & Technical Confirmation Alerts - Bộ Nội Vụ
Cencora Inc.: Quiet Rally, Solid Fundamentals – Is This Healthcare Stock Still Underpriced? - AD HOC NEWS
Baird Adjusts Cencora Price Target to $415 From $392, Maintains Outperform Rating - marketscreener.com
What to expect from Cencora's next quarterly earnings report - MSN
Video Forum: Tim Cernohous, Cencora - Mass Market Retailers
Nordea Investment Management AB Increases Stock Holdings in Cencora, Inc. $COR - MarketBeat
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $164,000 Stock Position in Cencora, Inc. $COR - MarketBeat
Cencora, Inc. $COR Position Cut by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Tema Etfs LLC Invests $2.04 Million in Cencora, Inc. $COR - MarketBeat
First Horizon Corp Makes New $3.01 Million Investment in Cencora, Inc. $COR - MarketBeat
Published on: 2026-01-13 06:24:30 - Улправда
AOP Health’s Rapiblyk™ Now Accessible via Leading US Healthcare Improvement Companies - GlobeNewswire Inc.
Cencora, Inc. (COR) Stock Analysis: Exploring a 15.56% Potential Upside Amid Strong Analyst Confidence - DirectorsTalk Interviews
Aug Swings: Is Cencora Inc subject to activist investor interestPortfolio Performance Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Washington Trust Bank Has $14.56 Million Position in Cencora, Inc. $COR - MarketBeat
SG Americas Securities LLC Has $5.40 Million Stock Holdings in Cencora, Inc. $COR - MarketBeat
Spire Wealth Management Lowers Position in Cencora, Inc. $COR - MarketBeat
Nisa Investment Advisors LLC Raises Stake in Cencora, Inc. $COR - MarketBeat
Jim Cramer says “I like Cencora a lot” but notes “Cardinal Health’s got them all beat” - MSN
Cencora (COR) Valuation Check As Share Price Momentum Cools After Recent Gains - Yahoo Finance
What to Expect From Cencora's Next Quarterly Earnings Report - Barchart.com
PRN_FinancialWrapper | PR NewswireWhat to Expect From Cencora's Next Quarterly Earnings Report - FinancialContent
Why Cencora Inc. stock is rated strong buyPrice Action & Daily Profit Maximizing Trade Tips - ulpravda.ru
Why Cencora Inc. stock attracts high net worth investorsTrade Exit Report & Fast Gain Swing Trade Alerts - Улправда
Is Cencora Inc. stock a buy for dividend growth2025 Price Targets & AI Driven Price Predictions - ulpravda.ru
Is It Too Late To Consider Cencora (COR) After A 236% Five Year Run? - simplywall.st
Cencora Inc.: Quiet Rally, Big Expectations – Is The Stock Still A Buy After Its Recent Run? - AD HOC NEWS
How geopolitical tensions affect Cencora Inc. stockWeekly Profit Analysis & Smart Investment Allocation Tips - ulpravda.ru
Will Cencora Inc. stock recover faster than marketJuly 2025 Patterns & Fast Exit and Entry Trade Guides - ulpravda.ru
Will Cencora Inc. (ABG) stock outperform energy sector in 2025Recession Risk & Advanced Technical Signal Analysis - ulpravda.ru
Here's Why You Should Retain Cencora Stock in Your Portfolio Now - The Globe and Mail
Why Cencora (COR) is a Top Value Stock for the Long-Term - Yahoo Finance
Moran Wealth Management LLC Sells 3,180 Shares of Cencora, Inc. $COR - MarketBeat
CX Institutional Purchases 12,964 Shares of Cencora, Inc. $COR - MarketBeat
Why Cencora Inc. stock attracts HNW investorsHigh Frequency Trading Trends & We Spotted the Next Tesla – See Inside - ulpravda.ru
Here's Why Cencora (COR) is a Strong Growth Stock - Yahoo Finance
Cencora, Inc. $COR Stock Position Lowered by Sivik Global Healthcare LLC - MarketBeat
Robeco Institutional Asset Management B.V. Purchases 20,713 Shares of Cencora, Inc. $COR - MarketBeat
Cencora bets big on oncology platform in $5 billion OneOncology deal - MSN
Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release - MarketScreener
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):